Patents by Inventor Mark E. Maxwell

Mark E. Maxwell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CDK9 as modifier of the IGF pathway and methods of use
    Patent number: 8758994
    Abstract: Human CDK9 genes are identified as modulators of the IGF pathway, and thus are therapeutic targets for disorders associated with defective IGF function. Methods for identifying modulators of IGF, comprising screening for agents that modulate the activity of CDK9 are provided.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: June 24, 2014
    Assignee: Exelixis, Inc.
    Inventors: Mark E. Maxwell, Michael Martin Ollmann, Timothy S. Heuer, Lynn Margaret Bjerke
  • ALDOs as modifiers of the IGF pathway and methods of use
    Patent number: 7927872
    Abstract: Human ALDO genes are identified as modulators of the IGF pathway, and thus are therapeutic targets for disorders associated with defective IGF function. Methods for identifying modulators of IGF, comprising screening for agents that modulate the activity of ALDO are provided.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: April 19, 2011
    Assignee: Exelixis, Inc.
    Inventors: Mark E. Maxwell, Michael Martin Ollmann, Timothy S. Heuer, Benjamin C. Hitz
  • ACACS As Modifiers of the IGF Pathway and Methods of Use
    Publication number: 20090053239
    Abstract: Human MPTEN genes are identified as modulators of the PTEN pathway, and thus are therapeutic targets for disorders associated with defective PTEN function. Methods for identifying modulators of PTEN, comprising screening for agents that modulate the activity of MPTEN are provided.
    Type: Application
    Filed: June 20, 2005
    Publication date: February 26, 2009
    Applicant: EXELIXIS, INC.
    Inventors: Mark E. Maxwell, Michael Martin Ollmann, Timothy S. Heuer, Lynn Margaret Bjerke
  • ALDOS AS MODIFIERS OF THE IGF PATHWAY AND METHODS OF USE
    Publication number: 20090022737
    Abstract: Human ALDO genes are identified as modulators of the IGF pathway, and thus are therapeutic targets for disorders associated with defective IGF function. Methods for identifying modulators of IGF, comprising screening for agents that modulate the activity of ALDO are provided.
    Type: Application
    Filed: June 20, 2005
    Publication date: January 22, 2009
    Applicant: EXELIXIS, INC.
    Inventors: Mark E. Maxwell, Michael Martin Ollmann, Timothy S. Heuer, Benjamin C. Hitz
  • CRBs as Modifiers of Branching Morphogenesis and Methods of Use
    Publication number: 20080163386
    Abstract: Human CRB genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morphogenesis, comprising screening for agents that modulate the activity of CRB are provided.
    Type: Application
    Filed: January 28, 2007
    Publication date: July 3, 2008
    Applicant: EXELIXIS, INC.
    Inventors: Felix D. Karim, Linda Nolan Keyes, Gregory D. Plowman, Michael Martin Ollmann, Mark E. Maxwell, Thierry Tidiane Diagana
  • Modulators of RabGGT and methods of use thereof
    Publication number: 20040142888
    Abstract: The present invention provides methods for inducing apoptosis in a cell, the methods generally involving contacting the cell with an agent that reduces the level and/or activity of RabGGT. The present invention further provides methods for treating a disorder related to unwanted cell proliferation in an individual, the methods generally involving administering to the individual an agent that reduces the level and/or activity of RabGGT. The present invention further provides methods for reducing apoptosis in a cell, the methods generally involving increasing the level and/or activity of RabGGT in the cell. The present invention further provides methods for treating disorders associated with excessive apoptosis. The present invention further provides methods for identifying a cell that is amenable to treatment with the methods of the present invention. The present invention further provides methods for modulating a binding event between RabGGT and a RabGGT interacting protein.
    Type: Application
    Filed: August 7, 2003
    Publication date: July 22, 2004
    Inventors: Veeraswamy Manne, Mark Lynch, Petra B. Ross-MacDonald, Terry Stouch, Naomi Laing, Pamela Carroll, Kevin Fitzgerald, Louis J. Lombardo, Michael R. Costa, Mark E. Maxwell, Rachel M. Kindt, Mark R. Lackner, Tak Hung, Carol L. O'Brian, Hai Guang Zhang, Katherine S. Brown, Jae Moon Lee
  • CRBs as modifiers of branching morphogenesis and methods of use
    Publication number: 20030100005
    Abstract: Human CRB genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morphogenesis, comprising screening for agents that modulate the activity of CRB are provided.
    Type: Application
    Filed: November 25, 2002
    Publication date: May 29, 2003
    Inventors: Felix D. Karim, Linda Nolan Keyes, Gregory D. Plowman, Michael Martin Ollmann, Mark E. Maxwell, Thierry Tidiane Diagana